Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating NMR Restraints into Coarse-Grained Simulations: Toward Accurate Conformational Ensembles of Complex Protein Systems.

Journal of the American Chemical Society·2026
Same author

Aggregation and membrane activity of mutant A30P alpha-synuclein on mitochondrial membranes.

International journal of biological macromolecules·2026
Same author

Cellular prion protein and calcium ions trigger the neurotoxicity of α-synuclein aggregates.

Cell & bioscience·2025
Same author

Structural and cellular properties of human prion protein oligomers.

Communications biology·2025
Same author

Structure and Dynamics of the Misfolding Intermediate in the Pathogenic T183A Prion Protein Mutant.

Journal of chemical theory and computation·2025
Same author

GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis.

JHEP reports : innovation in hepatology·2025

Related Experiment Video

Updated: Jul 3, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

α-Synuclein aggregation landscape from phase separation to neurotoxic intermediates.

Silvia Arino1, Giuliana Fusco1, Alfonso De Simone1

  • 1Department of Pharmacy, University of Naples Federico II, Italy.

FEBS Letters
|July 2, 2026
PubMed
Summary

Parkinson's disease involves alpha-synuclein (αS) aggregation. This review highlights liquid-liquid phase separation (LLPS) as a key intermediate, suggesting new therapeutic strategies targeting αS condensates.

Keywords:
amyloid intermediatesliquid–liquid phase separation (LLPS)neurodegenerationprotein condensatesα‐synuclein aggregation

More Related Videos

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Related Experiment Videos

Last Updated: Jul 3, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Aberrant aggregation of alpha-synuclein (αS) into amyloid fibrils is a hallmark of Parkinson's disease.
  • Transient intermediates in αS aggregation are linked to cellular toxicity but remain poorly understood.

Purpose of the Study:

  • To review the mechanistic principles of αS aggregation.
  • To emphasize the role of liquid-liquid phase separation (LLPS) as a critical intermediate in αS aggregation.
  • To discuss how αS structural evolution in condensed phases influences cellular dysfunction and disease propagation.

Main Methods:

  • Literature review of αS aggregation mechanisms.
  • Focus on liquid-liquid phase separation (LLPS) as a key intermediate step.
  • Analysis of the structural evolution of αS within condensed phases.

Main Results:

  • Liquid-liquid phase separation (LLPS) is identified as a critical intermediate in αS aggregation.
  • The structural changes of αS within condensed phases dictate cellular dysfunction and pathological spread.
  • A state-centric therapeutic paradigm is proposed, focusing on modulating αS condensate properties.

Conclusions:

  • Understanding αS aggregation intermediates, particularly LLPS, is crucial for Parkinson's disease research.
  • Modulating the physical properties of αS condensates offers a novel therapeutic strategy.
  • This approach presents a sophisticated alternative to traditional inhibition strategies for Parkinson's disease.